In March of 2023, the FDA's approval of Naloxone, often referred to as Narcan, for over-the-counter sale marked a pivotal decision for treating the opioid epidemic in the United States. While barriers still exist in ensuring widespread access to this life-saving medication, the immediate implications of this regulatory change cannot be underestimated.
Can Narcan training contribute to overcoming the...